23 results about "Serum antibody" patented technology

The application discloses application of a cryptosporidium cgd6_2310 protein as an oocyst outer wall marker protein, an amino acid sequence of which is shown in the sequence table SEQ ID N0.1; a cryptosporidium oocyst wall protein specific polypeptide, an amino sequence of which is CLTPQSIERKEGTIID or ELDSSRTPVNETINC; an anti-cryptosporidium oocyst outer wall protein antibody, which can specifically bind to the outer surface of the cryptosporidium oocyst outer wall; an anti-cryptosporidium oocyst outer wall specific polypeptide antibody, which is an antibody prepared by using the cryptosporidium oocyst wall protein specific polypeptide; application of the anti-cryptosporidium oocyst outer wall protein antibody or the anti-cryptosporidium oocyst outer wall protein specific polypeptide antibody in detection of cryptosporidium; the polypeptide rabbit serum antibody has good sensitivity; in detection of samples in the environment, the polypeptide antibody only recognizes the cryptosporidium oocyst and does not cross react, and has good specificity.

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The application belongs to the field of animal bacteriology and molecular biology technology, and relates to preparation of a hybridoma cell and application thereof. A monoclonal antibody is prepared through intracellular Lawsonia intracellularis outer membrane protein OmpA expressed by prokaryotes, and IFA, WB and blocking ELISA and other immunological detection methods for detecting or diagnosing Lawsonia intracellularis are established through the expressed intracellular Lawsonia intracellularis outer membrane protein OmpA and the prepared monoclonal antibody. The blocking ELISA for detecting serum antibodies of Lawsonia intracellularis can detect serum samples of suspected Lawsonia intracellularis infection from different species, and does not exist cross reaction with positive serum of common pig pathogens, has high sensitivity and specificity, is good in repeatability, and is suitable for high-throughput detection of serum samples.

The present application relates to the technical field of novel coronavirus, and particularly relates to a novel coronavirus trivalent DNA vaccine and a preparation method. The trivalent DNA vaccine takes a recombinant plasmid carrying a nucleotide sequence as shown in SEQ ID NO: 1 or 2 as an active ingredient. The trivalent DNA vaccine provided in the present application can express a fusion antigen protein of three kinds of antigen genes of the novel coronavirus in eukaryotic cells, and produce serum IgG antibodies against the three kinds of antigens of the novel coronavirus. In addition, the novel coronavirus trivalent DNA vaccine provided in the present application can immunize mice to produce T cells secreting various cytokines, and has a stronger T cell immune protection effect.

The invention relates to the technical field of poultry immunology, in particular to a universal riemerella anatipestifer monoclonal antibody, a detection kit and application of the universal riemerella anatipestifer monoclonal antibody. Specifically, the invention successfully designs the universal riemerella anatipestifer monoclonal antibody, and the detection kit developed based on the monoclonal antibody can rapidly detect the level of the riemerella anatipestifer serum antibody in a sample, and has high sensitivity and strong specificity. The riemerella anatipestifer strain has no cross reactivity with avian enterococcus faecalis, avian salmonella typhimurium, avian escherichia coli and avian salmonella enteritidis, so that the riemerella anatipestifer strain can be applied to rapid screening, epidemiological monitoring and vaccine immune effect evaluation of riemerella anatipestifer infection, and has a wide application prospect.

The invention discloses an immune effect evaluation method of a cysticercus cellulosae recombinant TPx protein vaccine, and belongs to the technical field of biological medicines. The vaccine takes recombinant thioredoxin peroxidase (TPx) from cysticercus cellulosae as an immunogen, and an adjuvant (such as a Freund's adjuvant) can be optionally supplemented to enhance the immune effect. A mouse is immunized through subcutaneous injection of the vaccine, it is proved that the vaccine can effectively induce an organism to generate humoral immune response and cellular immune response, specifically, the levels of serum IgG, IgG2a and IgG1 antibodies are remarkably increased, the proliferation capacity of splenic lymphocytes is enhanced, and the secretion levels of Th1 type cell factors (TNF-alpha and IL-12) and Th2 type cell factors (IL-13 and IL-10) are remarkably increased. The invention provides a new candidate vaccine for prevention of cysticercosis, and has important application value.

The application belongs to the technical field of biology and specifically relates to a SAT1 type foot-and-mouth disease virus monoclonal antibody 5G10, a kit and a detection method. The single-chain antibody 5G10 comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 6, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 7. The titer is greater than 1:128000, the heavy chain is IgG1 type, and the light chain is lambda type. The antibody can specifically combine with VP1 recombinant protein of the SAT1 type foot-and-mouth disease virus and has high specificity. The application of the monoclonal antibody 5G10 in a foot-and-mouth disease virus SAT1 type blocking ELISA antibody detection method is provided, and convenient and effective technical reserves are provided for border port detection and animal serum antibody screening of the SAT type foot-and-mouth disease.

The invention provides an orf virus double-antigen self-assembled nanoparticle, the nanoparticle is a fusion protein containing orf virus protein and ferritin, and the orf virus protein comprises orf virus protein ORFV 050 and orf virus protein ORFV 086. The ORFV050-ORFV086-Fel fusion protein prepared by the invention is self-assembled into nanoparticles in vitro, and can induce the generation of high-titer serum antibodies and cell factors such as IFN-gamma, TNF-alpha and IL-6 of an organism, so that the ORFV050-ORFV086-Fel fusion protein can be used for preparing vaccines for preventing and / or treating orf. Based on ORFV 050-ORFV086-Fir fusion protein, the self-assembled protein nanoparticle vaccine provided by the invention is safe and effective, can induce immune mice to generate lasting immune protection, has good immune efficacy, and can be clinically used for prevention and / or treatment of orf virus infection.

The kit for systemic lupus erythematosus detection comprises a lower box body, an upper box body, an upper placement groove, a lower placement groove, a strip-shaped air bag, a limiting rod, an inflation bag, an exhaust bag and a first flow dividing pipe, the upper box body is arranged above the lower box body in an overturning mode, the upper placement groove is formed in the inner side of the upper box body, the lower placement groove is formed in the inner side of the lower box body, and the strip-shaped air bag is arranged in the lower placement groove. The lower end face of the lower box body is provided with a limiting rod, an inflation bag and an exhaust bag, the lower end face of the lower box body is provided with an air exhaust bag, and a first flow dividing pipe is embedded in the lower end face of the lower box body, so that the problem that the protection effect of an original kit on a serum antibody reagent is poor is solved; the serum antibody reagent placing box is reasonable in structure, after a serum antibody reagent is placed, the strip-shaped air bag in the lower placing groove can be inflated by pulling the inflation bag so as to protect the serum antibody reagent, and the serum antibody reagent placing box is simple and convenient to use and high in practicability.

The invention provides a quantitative detection method of a porcine reproductive and respiratory syndrome serum antibody, and belongs to the technical field of veterinary immunological detection.The method comprises the steps that S1, a serum sample is collected and pretreated; s2, antibody marker extraction and characteristic parameter extraction; s3, feature processing and antibody signal enhancement based on four-algorithm fusion; and S4, quantitative calibration and antibody concentration output. Through closed-loop design of multi-algorithm fusion, accurate quantitative detection of the porcine reproductive and respiratory syndrome serum antibody is realized.

This invention relates to the field of avian immunology, and more particularly to a universal monoclonal antibody against Riemerella anatipestifer, a detection kit, and their applications. Specifically, this invention successfully designed a universal monoclonal antibody against Riemerella anatipestifer, and the detection kit developed based on this monoclonal antibody can rapidly detect the level of Riemerella anatipestifer serum antibodies in samples with high sensitivity and strong specificity. Furthermore, it shows no cross-reactivity with Enterococcus faecalis, Salmonella typhi, Escherichia coli, and Salmonella enteritidis, thus it can be used for rapid screening, epidemiological monitoring, and evaluation of vaccine immunization efficacy against Riemerella anatipestifer infection, with broad application prospects.

The invention discloses a B cell conservative epitope peptide of enterotoxigenic Escherichia coli V-type secretion system effect protein EatA and application thereof, and particularly relates to application in ETEC specific antibody diagnosis. The B cell conservative epitope peptide disclosed by the invention can be functionally displayed and expressed on the surface of an inert carrier S9H thallus, PT8 is displayed and expressed on the surface of the S9H thallus, and an agglutination test directly mediated by the PT8 and specifically recognized by an antibody is established, so that only ETEC pathogen infectious antibodies are specifically recognized, other pathogenic escherichia coli can be identified and diagnosed, and the B cell conservative epitope peptide has a good application prospect. And no cross reaction with serum antibodies of other infectious diseases exists. According to the method, the specific serum antibody can be detected 7 days after a Balb / c mouse is infected by the ETEC strain H10407. The diagnosis method is high in specificity, good in sensitivity, convenient to operate and intuitive in result judgment, and is expected to become a technical means for visual on-site accurate and convenient diagnosis of ETEC infection.

The invention discloses a preparation method and application of a colloidal gold test strip for detecting a group A rotavirus antibody. The gold-labeled protein used by the test strip is prokaryotically expressed and soluble RVA-VP6-3P recombinant protein, and the protein has rich group-specific epitopes, so that the specificity and sensitivity of the gold-labeled protein are ensured, the economic cost for obtaining and purifying the target protein is reduced, and a foundation is laid for establishment, popularization and application of an antibody detection method. The RVA-VP6-3P is labeled with colloidal gold, the detection line is coated with SPA, the quality control line is coated with a monoclonal antibody 1M1F9 capable of specifically recognizing the RVA-VP6-3P, and then the test strip is assembled. The test strip has no cross reactivity with positive serum antibodies of other common swine disease viruses, has the characteristics of convenience in operation, less time consumption, high sensitivity, strong specificity and the like, can complete the detection of the group A rotavirus antibody in 5-15 minutes, and is convenient for immediate use in a clinical first line.

The invention discloses a beta1-AA targeted immunoadsorption column and a preparation method thereof, and belongs to the field of heart failure treatment. The invention discloses a beta1-AA targeting immunoadsorption column and a preparation method thereof, and belongs to the technical field of heart failure treatment. According to the invention, a high-affinity ligand beta1-Pep-03 (SEQ ID NO.1) is screened by virtue of phage display and molecular docking technologies, and is fixed on agarose microspheres by virtue of an amino coupling method, so that the immunoadsorption column is assembled. The adsorption column can efficiently and specifically remove beta 1-AA in serum, remarkably reduce the serum antibody level in an animal model, improve the heart function and inhibit myocardial cell apoptosis and autophagy abnormality, and shows good biocompatibility; and a novel precise treatment tool is provided for patients with beta 1-AA positive heart failure.

This invention discloses a recombinant protein G3P1-12, its preparation method, and its applications, belonging to the field of DNA recombination technology in bioengineering. This invention utilizes phage display technology to clone a gene fragment encoding the N-terminal 1-12 peptide segment of the P53 protein into the PIII protein gene of a filamentous phage vector, preparing a recombinant protein displaying the P53 protein epitope. This recombinant protein is then displayed on the surface of phages for the detection of p53 antibodies in the serum of cancer patients. This invention also discloses the application of recombinant protein G3P1-12 in the preparation of a biological product for detecting p53 antibodies in the serum of cancer patients. This biological product has advantages such as high specificity, high sensitivity, simple preparation, and low cost.

The application provides a kind of organic high molecular nanoparticle vaccine targeting lysosome and its preparation method and application.The organic high molecular nanoparticle vaccine can target lysosome, promote antigen presenting cell maturation and proinflammatory cytokine secretion, improve serum antibody titer, and enhance the immune protection effect on pathogen infection.The application also provides an organic high molecular polymer for preparing organic high molecular nanoparticle vaccine, which can accurately co-deliver adjuvant and antigen, and has good biocompatibility, degradability, and can reduce immunogenicity and side effects.

The present application belongs to the field of immune detection technology, and particularly relates to a colloidal gold immunochromatographic test strip for detecting antibodies of multiple species of Toxoplasma gondii, a preparation method and application thereof. The test strip uses Staphylococcus aureus protein A as a detection line, and can detect serum antibodies in various animals such as pigs, sheep, goats and cats. A DNP system is used as an independent quality control line, avoiding the dependence of a traditional quality control line on the spatial conformation of SAG1 protein, and improving the stability and repeatability of the test strip. The test strip is used in combination with a sample diluent to detect negative samples, and the negative coincidence rate reaches 100%. The test strip is used in combination with a sample diluent to detect clinical serum samples, and the coincidence rate with IFA reaches 97.6-100%, indicating that the test strip and the sample diluent have good diagnostic reliability, specificity and accuracy, are portable and simple to operate, and can determine the result by naked eye within 5 minutes without relying on professional equipment, and are suitable for on-site rapid detection and clinical detection in farms.

The invention relates to the technical field of canine serum GnRH antibody detection, in particular to a method and a kit for detecting a GnRH antibody in canine serum. The KLH-GnRH dimer polypeptide is obtained by coupling a KLH dimer polypeptide with a GnRH dimer polypeptide; the amino acid sequence of the GnRH dimer polypeptide is as shown in SEQ ID NO. 1. The KLH-GnRH dimer polypeptide is used as an antigen, and an indirect ELISA method is adopted to detect the GnRH antibody titer, so that the hormone state and reproductive capacity of dogs at different stages are evaluated. The method has the advantages of low cost, simplicity and convenience in operation, high sensitivity, strong specificity, good accuracy and the like, stable, rapid, accurate and convenient dog serum GnRH antibody level detection can be realized, and meanwhile, the repeatability is good.

The present invention relates to the technical field of vaccine preparation, and particularly, to a bivalent inactivated EV71-CA16 vaccine, a method for preparing the same, and use thereof. The present invention implements the preparation by means of separately adsorbing a monovalent viral stock solution containing an EV71 antigen and a monovalent viral stock solution containing a CA16 antigen with an adjuvant and then mixing same, thereby improving the content of the EV71 antigen and the CA16 antigen in the vaccine substance and greatly improving the adsorption rate and recovery rate of EV71 and CA16 antigens. Moreover, the bivalent EV71-CA16 viral antigen can cause positive seroconversion and up-regulation of the corresponding neutralizing antibody and induce a higher serum antibody level, thus facilitating the preparation of the bivalent inactivated EV71-CA16 vaccine and preventing hand-foot-and-mouth disease.

The application discloses a reagent for detecting bovine nodular dermatopathy virus antibody and a polypeptide used by the reagent. The polypeptide provided by the application is an eA27-1 polypeptide or a complete polypeptide consisting of the eA27-1 polypeptide and an eA33-1 polypeptide; the eA27-1 is a polypeptide with an amino acid sequence shown in SEQ ID No. 1; and the eA33-1 is a polypeptide with an amino acid sequence shown in SEQ ID No. 5. The antibody detection kit prepared by using the conjugate of the polypeptide of the application as a coating agent has the advantages of high specificity, high sensitivity, high accuracy, simple operation and rapidness, and is suitable for rapid and large-scale screening and detection of bovine nodular dermatopathy infection serum antibody by grass-roots veterinary departments and entry-exit inspection and quarantine bureaus.

The application provides a characteristic protein of a serum type I chicken Marek's disease virus and a detection application, and belongs to the technical field of virus detection. The application provides a recombinant gene derived from the serum type I chicken Marek's disease virus, and the nucleotide sequence of the recombinant gene is shown as SEQ ID No. 1. The recombinant gene encodes MDV-1 recombinant PP38 protein, and the MDV-1 recombinant PP38 protein can be used for ELISA detection. The application also provides an ELISA detection kit constructed by using the MDV-1 recombinant PP38 protein, which can be used for clinical MDV-1 serum antibody detection, screening of SPF chickens, detection of exogenous virus antibodies of avian live vaccines or virus seeds and epidemiological investigation, so as to prevent and control the spread of MDV-1 infection.

This invention belongs to the field of biomedical technology and discloses a grouper neuronecrosis virus (NNV) vaccine, its preparation method, and its application. The invention connects the dominant NNV epitope CP4, the small molecule penetrating peptide LMWP, and grouper ferritin via a linker sequence to obtain a fusion gene fragment LCF. A recombinant expression vector is constructed based on the pET28a plasmid and expressed in *E. coli* to obtain the recombinant fusion protein rLCF. This protein aggregates and self-assembles into a nanocage-like structure based on its own characteristics, thus obtaining an NNV self-assembled vaccine. The NNV self-assembled vaccine can significantly enhance the level of specific serum antibodies and non-specific enzyme activity in grouper through immersion immunization and provides good protection after grouper infection with neuronecrosis virus (NNV), providing an important reference for the immunoprevention and control of this virus.